Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy

  • Michael A. Fifer
  • Igor F. Palacios
  • Danita M. Yoerger Sanborn
  • Ulrich Sigwart
Chapter

Abstract

Alcohol septal ablation (ASA) was introduced by Sigwart in 1994 as an alternative to septal myectomy in patients with hypertrophic obstructive cardiomyopathy and symptoms refractory to optimal medical therapy. Patient selection is based on careful individual evaluation of symptoms, associated co-morbidities, and echocardiographic and angiographic parameters. Studies have shown that the clinical success of ASA in patients with provocable obstruction is comparable to that in patients with obstruction at rest. The use of myocardial contrast echocardiography as an adjunct to the procedure has yielded higher success rates despite lower infarct sizes, in turn reducing complication rates. The principal complication of the procedure is atrioventricular block, for which permanent pacing is required in approximately 10% of patients. Evidence from non-randomized trials and meta-analyses indicates that ASA is similar to myectomy with respect to hemodynamic and functional improvement and mortality. Surgery is often preferred in younger patients and in those with severe hypertrophy of the septum (e.g., ≥30 mm). ASA is usually selected for elderly patients and those with co-morbid conditions that increase the risk of surgery.

References

  1. 1.
    Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.CrossRefGoogle Scholar
  2. 2.
    Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117(3):429–39.CrossRefGoogle Scholar
  3. 3.
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211–4.CrossRefGoogle Scholar
  4. 4.
    Lyne JC, Kilpatrick T, Duncan A, Knight CJ, Sigwart U, Fox KM. Long-term follow-up of the first patients to undergo transcatheter alcohol septal ablation. Cardiology. 2010;116(3):168–73.CrossRefGoogle Scholar
  5. 5.
    Rothman RD, Baggish AL, O'Callaghan C, et al. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. Am J Cardiol. 2012;110(8):1169–74.CrossRefGoogle Scholar
  6. 6.
    Lakkis N, Plana JC, Nagueh S, Killip D, Roberts R, Spencer WH. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol. 2001;88(5):583–6.CrossRefGoogle Scholar
  7. 7.
    Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York heart association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation. 2002;106(4):454–9.CrossRefGoogle Scholar
  8. 8.
    Patel P, Dhillon A, Popovic ZB, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015;8(7):e003132.CrossRefGoogle Scholar
  9. 9.
    Sorajja P, Pedersen WA, Bae R, et al. First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67(24):2811–8.CrossRefGoogle Scholar
  10. 10.
    Lu M, Du H, Gao Z, et al. Predictors of outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: an echocardiography and cardiovascular magnetic resonance imaging study. Circ Cardiovasc Interv. 2016;9(3):e002675.PubMedGoogle Scholar
  11. 11.
    Yang YJ, Fan CM, Yuan JQ, et al. Effectiveness of alcohol septal ablation in obstructive hypertrophic cardiomyopathy with versus without extreme septal hypertrophy. J Invasive Cardiol. 2016;28(3):99–103.PubMedGoogle Scholar
  12. 12.
    Kovacic JC, Khanna D, Kaplish D, Karajgikar R, Sharma SK, Kini A. Safety and efficacy of alcohol septal ablation in patients with symptomatic concentric left ventricular hypertrophy and outflow tract obstruction. J Invasive Cardiol. 2010;22(12):586–91.PubMedGoogle Scholar
  13. 13.
    Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–9.CrossRefGoogle Scholar
  14. 14.
    Kitamura M, Takayama M, Matsuda J, et al. Clinical characteristics and outcome of alcohol septal ablation with confirmation by nitroglycerin test for drug-refractory hypertrophic obstructive cardiomyopathy with labile left ventricular outflow obstruction. Am J Cardiol. 2015;116(6):945–51.CrossRefGoogle Scholar
  15. 15.
    Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98(22):2415–21.CrossRefGoogle Scholar
  16. 16.
    Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1998;32(1):225–9.CrossRefGoogle Scholar
  17. 17.
    Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv. 1999;47(4):462–6.CrossRefGoogle Scholar
  18. 18.
    Harada T, Ohtaki E, Sumiyoshi T. Papillary muscles identified by myocardial contrast echocardiography in preparation for percutaneous transluminal septal myocardial ablation. Acta Cardiol. 2002;57(1):25–7.CrossRefGoogle Scholar
  19. 19.
    Veselka J, Zemánek D, Tomasov P, Duchonová R, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Heart Vessel. 2009;24(1):27–31.CrossRefGoogle Scholar
  20. 20.
    Alkhouli M, Sajjad W, Lee J, et al. Prevalence of non-left anterior descending septal perforator culprit in patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. Am J Cardiol. 2016;117(10):1655–60.CrossRefGoogle Scholar
  21. 21.
    Chen AA, Palacios IF, Mela T, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97(2):264–9.CrossRefGoogle Scholar
  22. 22.
    Chang SM, Nagueh SF, Spencer WH, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42(2):296–300.CrossRefGoogle Scholar
  23. 23.
    Baggish AL, Smith RN, Palacios I, et al. Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart. 2006;92(12):1773–8.CrossRefGoogle Scholar
  24. 24.
    Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97(10):1511–4.CrossRefGoogle Scholar
  25. 25.
    Veselka J, Duchonová R, Procházková S, et al. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol. 2004;60(2):133–6; discussion 137.PubMedGoogle Scholar
  26. 26.
    van Dockum WG, Beek AM, ten Cate FJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005;111(19):2503–8.CrossRefGoogle Scholar
  27. 27.
    Faber L, Welge D, Hering D, et al. Percutaneous septal ablation after unsuccessful surgical myectomy for patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2008;97(12):899–904.CrossRefGoogle Scholar
  28. 28.
    Veselka J, Jensen MK, Liebregts M, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry. Eur Heart J. 2016;37:1517.CrossRefGoogle Scholar
  29. 29.
    Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol. 2006;19(4):319–27.CrossRefGoogle Scholar
  30. 30.
    Liebregts M, Steggerda RC, Vriesendorp PA, et al. Long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in the young and the elderly. JACC Cardiovasc Interv. 2016;9(5):463–9.CrossRefGoogle Scholar
  31. 31.
    Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart. 2004;90(6):638–44.CrossRefGoogle Scholar
  32. 32.
    Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999;34(4):1123–8.CrossRefGoogle Scholar
  33. 33.
    Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103(11):1492–6.CrossRefGoogle Scholar
  34. 34.
    Jassal DS, Neilan TG, Fifer MA, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2006;27(15):1805–10.CrossRefGoogle Scholar
  35. 35.
    Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 1999;99(3):344–7.CrossRefGoogle Scholar
  36. 36.
    Chen YZ, Qiao SB, Hu FH, et al. Biventricular reverse remodeling after successful alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015;115(4):493–8.CrossRefGoogle Scholar
  37. 37.
    Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2011, 2011. Published online Nov 8, 2011.  https://doi.org/10.1016/j.jacc.2011.06.011.
  38. 38.
    Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and Management of Hypertrophic Cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.CrossRefGoogle Scholar
  39. 39.
    Reinhard W, Ten Cate FJ, Scholten M, De Laat LE, Vos J. Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(8):1064–6.CrossRefGoogle Scholar
  40. 40.
    Wykrzykowska JJ, Kwaku K, Wylie J, et al. Delayed occurrence of unheralded phase IV complete heart block after ethanol septal ablation for symmetric hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2006;29(6):674–8.CrossRefGoogle Scholar
  41. 41.
    Kuhn H, Welge D, Hering D, et al. Percutaneous septal ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2008;97(4):234–43.CrossRefGoogle Scholar
  42. 42.
    Lawrenz T, Obergassel L, Lieder F, et al. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005;28(4):295–300.CrossRefGoogle Scholar
  43. 43.
    Cuoco FA, Spencer WH, Fernandes VL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(21):1718–23.CrossRefGoogle Scholar
  44. 44.
    Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2016;105(11):953–61.CrossRefGoogle Scholar
  45. 45.
    Jensen MK, Prinz C, Horstkotte D, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99(14):1012–7.CrossRefGoogle Scholar
  46. 46.
    Sorajja P, Ommen SR, Holmes DR, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126(20):2374–80.CrossRefGoogle Scholar
  47. 47.
    Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38(6):1701–6.CrossRefGoogle Scholar
  48. 48.
    Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol. 2007;50(9):831–4.CrossRefGoogle Scholar
  49. 49.
    Agarwal S, Tuzcu EM, Desai MY, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55(8):823–34.CrossRefGoogle Scholar
  50. 50.
    Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J. 2009;30(9):1080–7.CrossRefGoogle Scholar
  51. 51.
    Fifer MA. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation. 2007;116(2):207–16; discussion 216.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael A. Fifer
    • 1
  • Igor F. Palacios
    • 1
  • Danita M. Yoerger Sanborn
    • 1
  • Ulrich Sigwart
    • 2
  1. 1.Cardiology Division, Department of MedicineMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Cardiology Center, L’Université de GenèveGenevaSwitzerland

Personalised recommendations